IRWD — IRONWOOD PHARMACEUTICALS INC
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1446847 ·
Last close
$4.87
Market Cap
$806.23M
52W High
$5.78
52W Low
$2.95
ADV30
2,303,760
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | — | — | — | — | — | — | — |
| Jun 2026 | 113,041,000 | — | 79,307,000 | 51,291,000 | 285,128,000 | 79,127,000 | 446,971,000 |
| Mar 2026 | 106,506,000 | — | 72,533,000 | 40,773,000 | 434,566,000 | 220,471,000 | 651,710,000 |
| Dec 2025 | 47,709,000 | — | 6,553,000 | -2,276,000 | 396,901,000 | 215,456,000 | 658,736,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$185,555,000
Investing CF
$-1,000
Financing CF
$-199,575,000
CapEx
$-35,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$0.90
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,581,654,000
Inventory
—
Receivables
$112,732,000
ST Investments
—
EBIT TTM
$239,867,000
Pretax Income TTM
$207,378,000
Interest Exp TTM
$32,489,000
Analysts
4
Yahoo Snapshot (yfinance, live)
Total Revenue
$400,296,000
EBITDA
$253,560,000
Free Cash Flow
$121,834,752
Enterprise Value
$973,723,072
Total Cash
$86,376,000
Total Debt
$336,209,984
Shares Out
165,550,760
Trailing EPS
$0.90
Book Value
$-0.59
ROE
—
ROA
45.8%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 296,151,000 | 118,759,000 | 24,017,000 | 396,901,000 | 658,736,000 | -261,835,000 | 127,044,000 |
| Dec 2024 | 351,410,000 | 95,717,000 | 880,000 | 350,908,000 | 652,243,000 | -301,335,000 | 103,549,000 |
| Dec 2023 | 442,735,000 | 168,336,000 | -1,002,239,000 | 471,073,000 | 817,368,000 | -346,295,000 | 183,427,000 |
| Dec 2022 | 410,596,000 | 250,337,000 | 175,065,000 | 1,100,519,000 | 448,141,000 | 652,378,000 | 273,763,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$389,316,000
NetIncome TTM
$129,868,000
OpCashFlow TTM
—
Assets (Latest)
$285,128,000
Forward EPS
$1.50
Max Pain — expiry 2027-02-19
max pain strike: $2.50 · spot: $4.78 · call oi: 7,975 · put oi: 154
Expected Move to 2027-02-19:
±$1.40
(29.29%) —
implied range
$3.38 –
$6.18
· ATM straddle on $5.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| RIGL | RIGEL PHARMACEUTICALS INC | $808.18M | $42.92 | — |
| ARDX | ARDELYX, INC. | $799.36M | $3.18 | — |
| COLL | COLLEGIUM PHARMACEUTICAL, INC | $793.98M | $25.55 | — |
| LXRX | LEXICON PHARMACEUTICALS, INC. | $792.52M | $1.78 | — |
| SNDX | Syndax Pharmaceuticals Inc | $828.26M | $9.20 | — |
News headlines (Yahoo Finance, 1h cache)
Ironwood Pharmaceuticals Inc (IRWD) (Q3 2026) Earnings Call Highlights: Record LINZESS Sales ...
2026-11-06 01:14 · Yahoo
Ironwood (IRWD) Q3 2026 Earnings Call Transcript
2026-11-05 22:07 · Yahoo
What Ironwood Pharmaceuticals (IRWD) Said on Its Q3 Earnings Call
2026-11-05 21:14 · Yahoo
Ironwood Pharmaceuticals (IRWD) Beats Q3 Earnings Estimates
2026-11-05 13:35 · Yahoo
Ironwood: Q3 Earnings Snapshot
2026-11-05 12:15 · Yahoo
Ironwood Pharmaceuticals Raises Full-Year 2026 Financial Guidance Driven by Continued LINZESS U.S. Net Sales Growth and Strong Third Quarter Financial Performance
2026-11-05 12:05 · Yahoo
Ironwood Pharmaceuticals to Host Third Quarter 2026 Investor Update Call
2026-10-28 20:05 · Yahoo
Ironwood Pharmaceuticals Appoints Tammi Gaskins as Chief Executive Officer
2026-10-16 11:30 · Yahoo
Ironwood Pharmaceuticals to Participate in the Wells Fargo 21st Annual Healthcare Conference
2026-09-03 20:05 · Yahoo
Ironwood (IRWD) Q2 2026 Earnings Call Transcript
2026-08-13 17:43 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.